Helio Genomics is an AI-driven healthcare company on a mission to save lives by developing technology that can detect cancer early from a simple blood draw. We are pioneers of a true multi-modal x multi-omics approach to biomarker discovery – optimizing the best combination of biological data to unveil a clear picture of how cancer exists and evolves. In doing so, we challenge cancer by translating those learnings into user-friendly, accessible tools that guide medical decision-making to prevent cancer from progressing. Helio Genomics is headquartered in the United States with offices in California and Indiana. Helio Genomics is a multinational business with collaborations in both the United States and China, including leading scientists, physicians, research institutions, and business leaders from both countries. Helio Genomics strives to combine the experiences of these innovators and achievers in order to provide the most accurate and safest diagnostic technologies to everyone. Helio Genomics has CLIA and CAP certified laboratories, 3rd party laboratories, and cGMP facilities all working towards the endeavor of bringing these first-class technologies into the medical community.